B7-H4 Targeted Antibody-Drug Conjugates for the Treatment of Cancer

JP2025517340A5Pending Publication Date: 2026-05-22MERSANA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
MERSANA THERAPEUTICS INC
Filing Date
2023-05-17
Publication Date
2026-05-22

AI Technical Summary

Technical Problem

Current therapeutic modalities for advanced cancer, including radiation therapy and conventional chemotherapy, often fail to effectively treat cancers with overexpressed B7-H4, leading to poor prognosis and the need for new therapeutic agents that target B7-H4's biological activity.

Method used

Administration of a B7-H4-targeting antibody-drug conjugate (XMT-1660) specifically binding to the extracellular region of B7-H4, conjugated with a fully synthetic macromolecular linker-payload containing auristatin F-hydroxypropylamide, delivered intravenously at varying doses and frequencies.

Benefits of technology

The B7-H4-targeting antibody-drug conjugate demonstrates antitumor efficacy in preclinical models of endometrial and ovarian cancers, offering a potential therapeutic option for B7-H4-positive cancers that have progressed despite standard treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
Patent Text Reader

Abstract

Disclosed herein are dosing regimens for B7-H4 targeted antibody-drug conjugates for treating cancer. TIFF2025517340000029.tif115128
Need to check novelty before this filing date? Find Prior Art